eCOA software for better clinical trials
eCOAs (electronic Clinical Outcome Assessments) and digital outcome measures delivered at industry-leading speed and quality to enhance your trial findings and fuel medical breakthroughs.
eCOA+ is part of Medable's unified data collection platform, which includes eConsent, telehealth, and sensors, with standardized integrations into your existing clinical ecosystem.
Medable eCOA+
Faster study build time
Pre-built and validated instruments
Available languages
Take eCOA off the critical path
Rapidly deploy quality studies and take eCOA off the critical path of study start-up with a reusable instrument library of 380+ standardized workflows and AI-enabled, purpose-built technology so you can work on what matters most, advancing patient care.
Unlock insights with real-time data capture
Capture objective and subjective participant data in a standardized and compliant manner. Medable’s eCOA+ combines eClinROs, ePROs, ePerfOs, eObsROs, and digital measures, so you can uncover clinically meaningful insights in real-time.
Engage patients with a better experience
Medable’s eCOA clinical trial solution improves inclusivity and accessibility, meeting the needs of patients in any geographic location and across diverse therapeutic areas, reducing burden and increasing retention.
The Medable difference
Reusable eCOA Library
Our library of 380+ reusable, pre-validated instruments, assessments and diaries ensure a standardized, consistent method of data collection that drives real-time decision making.
BYOD and provisioned devices
Accessible across web and/or mobile, provisioned devices or BYOD, unlocking patient populations that were previously out of reach while increasing patients' optionality.
Cross-platform TeleVisit
One seamless platform experience allows site and patient users to better engage and participate in a comfortable environment, reducing burden and increasing compliance.
Digital measures
Standardized integrations for sensors capturing digital physiological measures provide value across a variety of therapeutic areas including Oncology, Immunology, Cardiovascular, and more.
User friendy Platform
Consumer-grade UX, complete with notifications, reports, and submission-ready data, is vetted by our Patient Caregiver Network (PCN) and clinicians, ensuring accessibility.
24/7 Customer Support
Global customer care support throughout your trial for sites, patients and study teams. Our team ensure the best user experience to enable seamless technology adoption, protocol compliance, and overall user satisfaction.
Globally Compliant
Available in 70+ countries and 120+ locales, Medable’s platform adheres to standards set by the FDA, CFR21 Part 11, HIPAA, and GDPR.
Powered by AI
By harnessing intelligent automation, we can reduce delivery timelines by up to 50%, enabling an accelerated study start up to quickly capture novel endpoints.
A top 10 pharmaceutical company approached Medable seeking support for their Phase III diabetes study in the highly competitive weight loss market. Their primary goal was to reduce the client’s average study build timelines from 16-20 weeks, down to just 8 weeks, a reduction of more than 50%.See how Medable was able to meet the customer's goal with this case study.
eCOA+ Streamlined Evidence Generation
Frequently asked questions
eCOA stands for electronic clinical outcome assessment and uses electronic devices like tablets, desktop computers, and phones to collect data from trial participants. Participants complete diaries, questionnaires, or other prompts to communicate how they are feeling or functioning during the course of a clinical trial. eCOAs are part of the decentralized clinical trial (DCT) methodology and are essential to understanding whether a drug is reducing symptoms and improving patients’ quality of life.
Medable’s eCOA offering is part of our broader evidence generation offering: Patient-First Data Collection. Medable’s tools allow teams to build eCOA instruments (both validated instruments and eDiaries) that meet industry standards. Data collected from this system can be used for primary endpoints in pivotal studies. Study teams can store instruments, including translations, in a library for rapid deployment in future studies. Dashboards keep teams informed of all startup activities along the way. Teams may also access their library of prebuilt, validated instruments to improve study startup.
Yes. Medable's platform is multimodal, meaning patients can access our interface through the Patient app or a web browser. A BYOD model allows patients to use their own smartphone or other device for data capture during a site visit or remotely. Participants using devices they are already familiar with may lead to better compliance and ultimately, a better clinical trial experience. However, since some participants may be hesitant to download an app on their own device, or may not own a device that meets the requirements, it’s important to anticipate a percentage of provisioned devices, even in trials adopting a BYOD strategy.
The latest in eCOA
.jpg)
Building a “gold standard” clinical trial experience in Japan
When talking to customers conducting their first multi-country trial, we sometimes liken clinical trials to spider webs. Just as a garden spider’s web differs from a black widow’s, clinical trials follow unique patterns in every region. Each country comes with its own set of rules, ethical standards, approval processes, and data privacy laws. Cultural factors also play a crucial role in how patients are recruited and understand Clinical trials, requiring sensitive communication and a deep respect for participants’ needs.
In Japan, these regulatory and cultural intricacies form a complex ‘web,’ with anchor points and structural requirements that, when understood and implemented correctly, create a framework for success. However, conducting Clinical trials in Japan has historically posed challenges for Sponsors and Contract Research Organizations (CROs). When we first entered the region, one Sponsor consistently cited issues with eCOA solutions and site and patient support, not fully adapting to Japan’s unique requirements. This feedback, combined with our own experiences on the ground, revealed a clear need for improvement.
Today, we can proudly say that the solutions we put in place have transformed Japan’s Clinical trial landscape, and what was once a challenge has now become the “gold standard” for supporting Clinical trials in the region.
SCOPE 2025: Trends, insights, and news
This year’s Scope Summit once again brought thousands in the clinical research space together, offering a glimpse into the evolving operational and technological landscapes shaping the future of trials.
J.P.M. Week 2025
The J.P. Morgan Healthcare Conference returned to San Francisco this year, bringing significant deals and strategic shifts that signal where healthcare is headed. While this year’s weather outside was dry and sunny, a substantial change from the prior two years' rainy conferences, the conditions inside differed, with several companies making waves.